In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs

Chemical Research in Toxicology

Volumn 25, Issue 8, 2012, Pages 1616-1632

  Thompson, Richard A ^a   Isin, Emre M ^a   Li, Yan ^b   Weidolf, Lars ^a   Page, Ken ^b   Wilson, Ian ^b   Swallow, Steve ^b   Middleton, Brian ^b   Stahl, Simone ^b   Foster, Alison J ^b   Dolgos, Hugues ^a,c   Weaver, Richard ^b,d   Kenna, J Gerry ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c MERCK SERONO S A   (Switzerland)

^d Sygnature Discovery Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; AMLODIPINE; AMODIAQUINE; BENZBROMARONE; BILE SALT; BROMFENAC; CARBAMAZEPINE; CELECOXIB; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 3A4; DICLOFENAC; FENCLOZIC ACID; FLUTAMIDE; GALACTOSE; GLUCOSE; IBUFENAC; IMILOXAN; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN 2; NEFAZODONE; PARACETAMOL; RITONAVIR; SUPROFEN; TICLOPIDINE; TIENILIC ACID; TROGLITAZONE; UNINDEXED DRUG; VIRUS ANTIGEN; ZOMEPIRAC;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IDIOSYNCRATIC ADVERSE REACTION; IN VITRO STUDY; ISOTOPE LABELING; LIVER CELL; NONHUMAN; RAT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIMIAN VIRUS 40;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL SURVIVAL; CYTOCHROME P-450 CYP3A; GALACTOSE; GLUCOSE; HEP G2 CELLS; HUMANS; MITOCHONDRIA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS;

EID: 84865208356     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx300091x     Document Type: Article

References (72)

1. Greaves, P., Williams, A., and Eve, M. (2004) First dose of potential new medicines to humans: how animals help Nat. Rev. Drug Discovery 3, 226-236 (Pubitemid 38379989)
2. Patel, H., Bell, D., Molokhia, M., Srishanmuganathan, J., Patel, M., Car, J., and Majeed, A. (2007) Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005 BMC Clin. Pharmacol. 7, 9
3. Wysowski, D. K. and Swartz, L. (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions Arch. Intern. Med. 165, 1363-1369 (Pubitemid 40973418)
4. Edwards, I. R. and Aronson, J. K. (2000) Adverse drug reactions: definitions, diagnosis, and management Lancet 356, 1255-1259
5. Baumann, A. (2009) Nonclinical development of biopharmaceuticals Drug Discovery Today 14, 1112-1122
6. Clarke, J. B. (2010) Mechanisms of adverse drug reactions to biologics Handb. Exp. Pharmacol. 196, 453-474
7. Ulrich, R. G. (2007) Idiosyncratic toxicity: a convergence of risk factors Annu. Rev. Med. 58, 17-34 (Pubitemid 46706498)
8. Greer, M. L., Barber, J., Eakins, J., and Kenna, J. G. (2010) Cell based approaches for evaluation of drug-induced liver injury Toxicology 268, 125-131
9. Lucena, M. I. 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex Hepatology 49, 2001-2009
10. Thompson, R. A., Isin, E. M., Li, Y., Weaver, R., Weidolf, L., Wilson, I. D., Claesson, A., Page, K., Dolgos, H., and Kenna, J. G. (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development Chem.-Biol. Interact. 192, 65-71
11. Greer, M. L., Smith, T. J. D., and Kenna, J. G. (2009) Mechanisms of drug hepatotoxicity in man: novel insights provided by the THLE-CYP cell panel Toxicology 262, 4-4
12. Dykens, J. A. and Will, Y. (2007) The significance of mitochondrial toxicity testing in drug development Drug Discovery Today 12, 777-785 (Pubitemid 47362789)
13. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans Drug Metab. Dispos. 40, 130-138
14. Colombo, F., Armstrong, C., Duan, J., and Rioux, N. (2011) A high throughput in vitro mrp2 assay to predict in vivo biliary excretion Xenobiotica 1-7
15. Obach, R. S., Kalomtkar, A. S., Soglia, J. R., and Zhao, S. X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose Chem. Res. Toxicol. 21, 1814-1822
16. Bauman, J. N., Kelly, J. M., Tripathy, S., Zhao, S. X., Lam, W. W., Kalgutkar, A. S., and Obach, R. S. (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction Chem. Res. Toxicol. 22, 332-340
17. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., and Okazaki, O. (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37, 1970-1977
18. Usui, T., Mise, M., Hashizume, T., Yabuki, M., and Komuro, S. (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins Drug Metab. Dispos. 37, 2383-2392
19. Noe, J., Stieger, B., and Meier, P. J. (2002) Functional expression of the canalicular bile salt export pump of human liver Gastroenterology 123, 1659-1666 (Pubitemid 35231665)
20. Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Jr, Lightfoot-Dunn, R., and Hamadeh, H. K. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development Toxicol. Sci. 118, 485-500
21. Day, S. H., Mao, A., White, R., Schulz-Utermoehl, T., Miller, R., and Beconi, M. G. (2005) A semi-automated method for measuring the potential for protein covalent binding in drug discovery J. Pharmacol. Toxicol. Methods 52, 278-285 (Pubitemid 41207205)
22. Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C., and Humphreys, W. G. (2009) In vitro screening of 50 highly prescribed drugs for thiol adduct formation - comparison of potential for drug-induced toxicity and extent of adduct formation Chem. Res. Toxicol. 22, 690-698
23. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., and Chalasani, N. (2008) Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals Hepatology 47, 2003-2009 (Pubitemid 351945567)
24. Munro, K. M., Walker, C. L., Stahl, S., Dawson, S., Kenna, G., Brown, D., Haddrick, M., and Valentin, J. P. (2011) A fluorescent BSEP inhibition assay: A novel in vitro tool for predictive toxicology J. Pharmacol. Toxicol. Methods 64, e12
25. Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., and Aleo, M. D. (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24, 1345-1410
26. Roma, M. G., Crocenzi, F. A., and Sanchez Pozzi, E. A. (2008) Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects Clin. Sci. (London) 114, 567-588 (Pubitemid 351589057)
27. Stieger, B. and Geier, A. (2011) Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis Expert Opin. Drug Metab. Toxicol. 7, 411-425
28. Nies, A. T. and Keppler, D. (2007) The apical conjugate efflux pump ABCC2 (MRP2) Pflugers Arch. 453, 643-659 (Pubitemid 46192536)
29. Jemnitz, K., Heredi-Szabo, K., Janossy, J., Ioja, E., Vereczkey, L., and Krajcsi, P. (2010) ABCC2/Abcc2: a multispecific transporter with dominant excretory functions Drug Metab. Rev. 42, 402-436
30. Elferink, R. O. and Groen, A. K. (2002) Genetic defects in hepatobiliary transport Biochim. Biophys. Acta 1586, 129-145 (Pubitemid 34311829)
31. Dambach, D. M., Andrews, B. A., and Moulin, F. (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models Toxicol. Pathol. 33, 17-26 (Pubitemid 40216800)
32. Benbow, J. W., Aubrecht, J., Banker, M. J., Nettleton, D., and Aleo, M. D. (2010) Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies Toxicol. Lett. 197, 175-182
33. Vignati, L., Turlizzi, E., Monaci, S., Grossi, P., Kanter, R. d., and Monshouwer, M. (2005) An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics Toxicology 216, 154-167 (Pubitemid 41712005)
34. Hosomi, H., Fukami, T., Iwamura, A., Nakajima, M., and Yokoi, T. (2011) Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation Drug Metab. Dispos. 39, 1388-1395
35. Grime, K., Webborn, P. J., and Riley, R. J. (2008) Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes Drug Metab. Dispos. 36, 1670-1678
36. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17, 3-16 (Pubitemid 38134055)
37. Hinson, J. A., Roberts, D. W., and James, L. P. (2010) Mechanisms of acetaminophen-induced liver necrosis Handb. Exp. Pharmacol. 369-405
38. Smith, D. A., Harrison, A., and Morgan, P. (2011) Multiple factors govern the association between pharmacology and toxicity in a class of drugs: toward a unification of class effect terminology Chem. Res. Toxicol. 24, 463-474
39. Boelsterli, U. A. (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity Toxicol. Appl. Pharmacol. 192, 307-322 (Pubitemid 37311346)
40. Bennett, W. E., Jr., Turmelle, Y. P., and Shepherd, R. W. (2009) Ibuprofen-induced liver injury in an adolescent athlete Clin. Pediatr. 48, 84-86
41. Myers, T. G., Dietz, E. C., Anderson, N. L., Khairallah, E. A., Cohen, S. D., and Nelson, S. D. (1995) A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3′-hydroxyacetanilide Chem. Res. Toxicol. 8, 403-413
42. Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., Rossner, S., and RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365, 1389-1397 (Pubitemid 40523733)
43. Henness, S., Robinson, D. M., and Lyseng-Williamson, K. A. (2006) Rimonabant Drugs 66, 2109-19 (Pubitemid 46372361)
44. 2120-2121.
45. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., and Astrup, A. (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370, 1706-1713 (Pubitemid 350100788)
46. Roth, R. A. and Ganey, P. E. (2010) Intrinsic versus idiosyncratic drug-induced hepatotoxicity - two villains or one? J. Pharmacol. Exp. Ther. 332, 692-697
47. Uetrecht, J. (2009) Immune-mediated adverse drug reactions [review] Chem. Res. Toxicol. 22, 24-34
48. Jones, H. M., Dickins, M., Youdim, K., Gosset, J. R., Attkins, N. J., Hay, T. L., Gurrell, I. K., Logan, Y. R., Bungay, P. J., Jones, B. C., and Gardner, I. B. (2012) Application of PBPK modelling in drug discovery and development at Pfizer Xenobiotica 42, 94-106
49. Park, B. K. 2011, Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discovery 10, 292-306
50. Daly, A. K. (2012) Using genome-wide association studies to identify genes important in serious adverse drug reactions Annu. Rev. Pharmacol. Toxicol 52, 21-35
51. Pirmohamed, M. (2010) Pharmacogenetics of idiosyncratic adverse drug reactions Handb. Exp. Pharmacol. 196) 477-491
52. Stricker, B. H. C. H., Ed. (1992) Drug-Induced Hepatic Injury, p 550, Elsevier, Amsterdam, The Netherlands.
53. Chan, T. Y. and Chan, A. W. (1996) Aminopyrine-induced blood dyscrasias: still a problem in many parts of the world Pharmacoepidemiol. Drug Saf. 5, 215-219 (Pubitemid 26273890)
54. Sweetman, S. C., Ed. Martindale: The Complete Drug Reference, Pharmaceutical Press [online]: London. (last accessed Dec 2011)
55. DailyMed, http://dailymed.nlm.nih.gov/dailymed/about.cfm?CFID= 107717732&CFTOKEN=99684cc89d7cb78a-658B6DA1-A310-3A45- DEC1A4F1BA66D2FC&jsessionid=ca309d30e7ce192f4366 (accessed Dec, 2011).
56. Arai, M., Yokosuka, O., Fujiwara, K., Kojima, H., Kanda, T., Hirasawa, H., and Saisho, H. (2002) Fulminant hepatic failure associated with benzbromarone treatment: a case report J. Gastroenterol. Hepatol. 17, 625-626 (Pubitemid 34748189)
57. Zimmerman, H. J. (1999) Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, p 789, Lippincott Williams & Wilkins, Philadelphia, PA.
58. Macfarlane, B., Davies, S., Mannan, K., Sarsam, R., Pariente, D., and Dooley, J. (1997) Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity Gastroenterology 112, 1707-1709 (Pubitemid 27181397)
59. Fitch, W. L., Chen, Y., Liu, L., Paehler, A., and Young, M. (2010) Application of modern drug metabolism structure determination tools and assays to the in vitro metabolism of imiloxan Drug Metab. Lett. 4, 77-87
60. Aranda-Michel, J., Koehler, A., Bejarano, P. A., Poulos, J. E., Luxon, B. A., Khan, C. M., Ee, L. C., Balistreri, W. F., and Weber, F. L., Jr. (1999) Nefazodone-induced liver failure: report of three cases Ann. Intern. Med. 130, 285-288 (Pubitemid 29091856)
61. Sandler, R. H. (1985) Anaphylactic reactions to zomepirac Ann. Emerg. Med. 14, 171-174 (Pubitemid 15162656)
62. Kaplowitz, N. and DeLeve, L. D., Eds. (2007) Drug Induced Liver Disease, p 816, Informa Healthcare: New York.
63. Miller, F. C., Schorr, W. J., and Lacher, J. W. (1983) Zomepirac-induced renal failure Arch. Intern. Med. 143, 1171-1173 (Pubitemid 13100651)
64. Reuben, A., Koch, D. G., Lee, W. M., and Acute Liver Failure Study Group (2010) Drug-induced acute liver failure: results of a U.S. multicenter, prospective study Hepatology 52, 2065-2076
65. Khemissa-Akouz, F., Ouguergouz, F., Sulem, P., Tkoub el, M., and Vaucher, E. (2002) Amlodipine-induced acute hepatitis Gastroenterol. Clin. Biol. 26, 637-638
66. El, H.,II, Malik, S. M., Alwakeel, H. R., Shaikh, O. S., Sasatomi, E., and Kandil, H. M. (2009) Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation World J. Gastroenterol. 15, 3937-3939
67. Sulkowski, M. S. (2004) Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors Clin. Infect. Dis. 38 (Suppl 2) S90-7
68. Floyd, J. S., Barbehenn, E., Lurie, P., and Wolfe, S. M. (2009) Case series of liver failure associated with rosiglitazone and pioglitazone Pharmacoepidemiol. Drug Saf. 18, 1238-1243
69. El-Naggar, M. H., Helmy, A., Moawad, M., Al-Omary, M., Al-Kadhi, Y., and Habib, B. (2008) Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma Ann. Pharmacother. 42, 713-718 (Pubitemid 351619944)
70. Burgunder, J. M., Abernethy, D. R., and Lauterburg, B. H. (1988) Liver injury due to verapamil Hepatogastroenterology 35, 169-170
71. Jadallah, K. A., Limauro, D. L., and Colatrella, A. M. (2003) Acute hepatocellular-cholestatic liver injury after olanzapine therapy Ann. Intern. Med. 138, 357-358 (Pubitemid 36205935)
72. Adler, E., Benjamin, S. B., and Zimmerman, H. J. (1986) Cholestatic hepatic injury related to warfarin exposure Arch. Intern. Med. 146, 1837-1839 (Pubitemid 16018934)